GLP-3, GLP1-R, reta: what seller code names mean
Online sellers of unapproved peptides often list weight-loss drugs under short codes instead of their real names. "GLP-3" is the best known. None of these codes is an official drug name, and none tells you what is in a vial.
There is no GLP-3 hormone and no GLP-3 drug class. The term is slang for retatrutide, Eli Lilly's experimental drug, which is not approved and cannot legally be sold for human use.
What the codes usually mean
| Name on a listing or in a post | Usually refers to | Where it is documented |
|---|---|---|
| GLP-3, "reta", "r3ta", "ratatouille" | Retatrutide | Public Citizen report, June 2026 |
| GLP1-R, GLP-1-R | Retatrutide | FDA warning letters, March 31, 2026 |
| Triple G | Retatrutide | Eli Lilly lawsuit, August 2026 |
| GLP1-T | Tirzepatide | FDA warning letter, March 31, 2026 |
| GLP-2 | Tirzepatide | FDA warning letter, March 31, 2026 |
| GLP1-S | Semaglutide | FDA warning letter, March 31, 2026 |
The codes are not standardized. The two FDA letters above show two sellers using different codes for the same drug in the same month, and sellers change them when a name gets blocked. Treat the table as a guide to what people mean, not as proof of what a product contains.
Where the numbers come from
The numbering counts hormone receptors. Semaglutide acts on one (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). Retatrutide acts on three (GLP-1, GIP and glucagon). Sellers turned that into "GLP-1", "GLP-2" and "GLP-3".
It is misleading. GLP-2 is a real and entirely different gut hormone that tirzepatide does not act on. And there is no hormone called GLP-3.
Why sellers and influencers use codes
- To get past filters. Public Citizen's 2026 investigation found that slang such as "GLP-3" and "r3ta" helps posts evade social media filters that block the drug's real name.
- To avoid naming a drug they cannot legally sell. Retatrutide is still in clinical trials. The FDA has said it cannot be used in compounding, and Lilly says it has flagged more than 14,000 websites, ads and listings offering it.
"Research use only" does not make it legal
Listings that use these codes usually carry a line such as "for laboratory research only, not for human consumption". The FDA has rejected that defense in writing. In a March 2026 warning letter, it said the disclaimer was contradicted by the seller's own website, which described weight loss, blood sugar and appetite effects in people. It also treated the bacteriostatic water the seller offered in a kit with a syringe as an unapproved drug.
Enforcement has not cleared the market. Public Citizen counted 14 FDA warning letters to retatrutide sellers since December 2024 and found that, as of May 2026, 11 of those sellers were still advertising retatrutide or other unapproved peptides.
What is known about the products
- Contents vary. Public Citizen cites a testing company that analyzed 2,759 samples sold as retatrutide. It rated 71 of 179 vendors as poor, bad or fraud. Many samples were impure, and others were stronger or weaker than labeled.
- People have been hospitalized. The same report found 26 adverse event reports for retatrutide in the FDA's database from January to May 2026, 11 of them involving hospitalization and three described as life-threatening.
- Injection raises the stakes. The FDA's letters note that an injected product bypasses the body's natural defenses against toxins and microorganisms.
- The drug itself is unfinished. Even the genuine molecule has no approved dose and an incomplete safety record. See our retatrutide page for the trial data.
In Lilly's words, what is sold on the black market "is not a medicine".
If you see one of these codes
- A code name on a product is a sign it is being sold outside the legal system. No licensed pharmacy dispenses "GLP-3".
- Semaglutide and tirzepatide are available legally by prescription. See semaglutide, tirzepatide and what they cost.
- To check a telehealth company before paying, use how to vet a provider.
- If you have already used a product like this and feel unwell, seek medical care and tell the clinician exactly what you took.
Sources
- FDA warning letter to Prime Sciences, March 31, 2026 (GLP1-R, GLP1-S, GLP1-T; research-use-only labeling)
- FDA warning letter to Gram Peptides, March 31, 2026, as archived by a third party ("GLP-1-R peptide", "GLP-2 peptide")
- Public Citizen, June 16, 2026: The "miracle drug" and the peptide craze breaking the FDA
- Healio, August 14, 2026: Eli Lilly files lawsuits against six companies for allegedly selling retatrutide
- Frier Levitt: analysis of Lilly's retatrutide lawsuits ("Triple G", 14,000 listings, FDA compounding statement)